In order to determine whether this clinically available treatment has similar effects to parent peptide unacylated ghrelin, the effect of AZP-531 on breast cancer cell growth was examined in MCF7, MDA-MB-468, and patient-derived TNBC cells, and compared to chemotherapeutic doxorubicin (Figure 6a–c). The gene discussed is GHRL; the disease is breast carcinoma.